ORGS
$2.52
Orgenesis
$.13
5.44%
ORGS
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Monday
Aug 22
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ORGS reports earnings?
Beat
Meet
Miss

Where is ORGS's stock price going from here?
Up
Flat
Down
Stock chart of ORGS
Analysts
Summary of analysts' recommendations for ORGS
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.